display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
Extensive stage SCLC (Es-SCLC)limited stage SCLC (ls-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)Extensive stage SCLC (Es-SCLC) - 1st Line (L1)limited stage SCLC (ls-SCLC) - maintenance (M)
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC CASPIAN ...
nivolumab plus ipilimumab CheckMate 451 ... STIMULI

Study type: